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A B S T R A C T
Stress is one of the factors underlying drug seeking behavior that often goes in parallel with loss of appetite. We
here demonstrate that orexin 1 receptors (OX⁠1R) may form heteromeric complexes with the corticotropin releas-
ing factor CRF⁠2 receptor. Two specific features of the heteromer were a cross-antagonism and a blockade by CRF⁠2
of OX⁠1R signaling. In cells expressing one of the receptors, agonist-mediated signal transduction mechanisms
were potentiated by amphetamine. Sigma 1 (σ⁠1) and 2 (σ⁠2) receptors are targets of drugs of abuse and, despite
sharing a similar name, the two receptors are structurally unrelated and their physiological role is not known.
We here show that σ⁠1 receptors interact with CRF⁠2 receptors and that σ⁠2 receptors interact with OX⁠1R. Moreover,
we show that amphetamine effect on CRF⁠2 receptors was mediated by σ⁠1R whereas the effect on OX⁠1 receptors
was mediated by σ⁠2R. Amphetamine did potentiate the negative cross-talk occurring within the CRF⁠2-OX⁠1 recep-
tor heteromer context, likely by a heteroreceptor complex involving the two sigma receptors and the two GPCRs.
Finally, in vivo microdialysis experiments showed that amphetamine potentiated orexin A-induced dopamine and
glutamate release in the ventral tegmental area (VTA). Remarkably, the in vivo orexin A effects were blocked by
a selective CRF⁠2R antagonist. These results show that amphetamine impacts on the OX⁠1R-, CRF⁠2R- and OX⁠1R/
CRF⁠2R-mediated signaling and that cross-antagonism is a unique tool for in vivo detection of GPCR heteromers.
1. Introduction
The first reference to a possible involvement of orexins in the ef-
fects of drugs of abuse appeared in 2003 and showed that orexigenic
peptide neurons respond to the chronic administration of morphine fol-
lowed by abrupt withdrawal symptoms caused by opioid receptor an-
tagonists (Georgescu et al., 2003). Subsequent studies examined the ef-
fect of orexigenic peptides in the reward mechanism associated with
consumption of drugs of abuse. It is today accepted that orexins have
an important role in responses associated with both food and drug re-
wards (Aston-Jones et al., 2010; Harris et al., 2005). The exact nature
of the effects of orexins in this context is unknown because of their com-
plex involvement in different aspects of drug addiction, aversive or ap-
petitive motivation, interactions with Pavlovian or instrumental learn-
ing processes and induced hedonic states.
Stress and drug addiction correlate in advanced societies. Therefore,
the mechanisms of stress and of reward must be interconnected. A rel-
evant regulator of stress responses is the corticotropin releasing fac-
tor (CRF), which is one of the main players in the hypothalamic–pitu-
itary–adrenal (HPA) axis (Gallagher et al., 2008). CRF is a peptide syn-
thesized and secreted by hypophysiotropic neurons that, in response to
stress, is released into the pituitary portal veins that give access to the
anterior pituitary gland. Therefore, CRF activates its cognate receptors
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and induces the release of the adrenocorticotropic hormone (ACTH) into
the systemic circulation, where it travels to its main target, the adrenal
gland. ACTH stimulates the synthesis and secretion of glucocorticoids in
the adrenal cortex (Bamberger et al., 1996). In fact, the actions of glu-
cocorticoids are mediated by glucocorticoid (GR) and mineral corticoid
(MR) receptors, that are widely expressed in the brain, including areas
involved in emotion, memory, and behavior such as the septum, hip-
pocampus, and prefrontal cortex (Morimoto et al., 1996; Viengchareun
et al., 2007).
A first aim of this paper was to investigate whether a drug of ad-
diction, namely amphetamine, affected the response of orexin or of CRF
receptors in a heterologous system. As orexin and CRF receptors belong
to the superfamily of G-protein-coupled receptors (GPCR), G-protein-de-
pendent and –independent signaling pathways were analyzed. As GPCRs
often form heteromeric complexes, the potential of receptors to form di-
rect receptor-receptor interactions was assayed and proved.
Sigma 1 receptors (σ⁠1R) are an atypical type of membrane recep-
tors whose exact function is not known. They have been proposed as
mediators of pluripotent modulation in living cells (Su et al., 2016)
and research on this protein is gaining momentum due to its potential
as target to combat neuropathic pain (Corbera et al., 2006; Mei and
Pasternak, 2002; Sun et al., 2016). In fact, the three-dimensional struc-
ture has been recently elucidated. σ⁠1R protomers, with a single trans-
membrane domain and a C-terminal tail having a cupin-like β-barrel
with a buried ligand-binding site, arranged into homotrimers (Schmidt
et al., 2016). Interestingly, it is a target of different drugs of abuse, co-
caine and methamphetamine among them (Cobos et al., 2008; Nguyen
et al., 2005). Due to the reports showing that σ⁠1R may interact with
metabotropic receptors for a variety of hormones/neurotransmitters,
it was tempting to speculate that the receptor may be regulating the
expression and function of GPCRs and of GPCR heteromers. As σ⁠1R
may form heteromers with corticotropin-releasing factor CRF⁠1 recep-
tor (Navarro et al., 2015), the occurrence of σ⁠1R-containing heterore-
ceptor complexes and the effect of amphetamine on orexin-CRF het-
eromeric-mediated signaling was also approached using in vitro experi-
ments.
2. Results
2.1. Orexin-1 receptors form heteromeric complexes with CRF⁠2 receptors in
a heterologous expression system
To determine whether orexin receptor 1 (OX⁠1R) colocalized at the
plasma membrane level with corticotropin-releasing factor 2 receptor
(CRF⁠2R), immunocytochemistry assays were undertaken in HEK-293T
cells transfected with 0.75μg cDNA for CRF⁠2R-YFP, 0.4μg cDNA for
OX⁠1R-RLuc or both. CRF⁠2R expression was detected by the YFP own
fluorescence while OX⁠1R expression was detected by a specific anti-
body against RLuc (1/100) followed by a secondary Cy3-antibody. OX⁠1R
showed a membrane localization and CRF⁠2R was localized at the plasma
membrane but also in intracellular structures (Fig. 1A). Colocalization
of both receptors was marked (detected in yellow in Fig. 1).
Immunocytochemistry assays are not suitable to demonstrate phys-
ical interactions. Thus, bioluminescence energy transfer (BRET) assays
were developed in HEK-293T cells expressing a constant amount of
OX⁠1R-RLuc and increasing amounts of CRF⁠2R-YFP. The saturation BRET
curve shown in Fig. 1B indicates a specific interaction between CRF⁠2R
and OX⁠1R (BRET⁠max 46±3 mBU, BRET⁠50 33±6) (Fig. 1B). As neg-
ative control, HEK-293T cells were transfected with the cDNA for
GHS-R1a-RLuc (0.75μg cDNA) and increasing amounts of the cDNA for
CRF⁠2R-YFP (0.1–1.2μg cDNA) and an unspecific linear signal was ob-
tained (Fig. 1B).
2.2. Functional characterization of CRF⁠2R-OX⁠1R heteromeric complexes
It is well established that GPCR heteroreceptor complexes display
unique properties that differ from those of the individual receptors.
To describe the heteromer-specific signaling characteristics, HEK-293T
cells coexpressing CRF⁠2R and OX⁠1R were treated with the specific an-
tagonist for CRF⁠2R, K41498 (1μM), the specific antagonist for OX⁠1R,
SB334867 (1μM) or vehicle, followed by activation of receptors with
CRF (100nM) and/or Orexin A (100nM). Four different techniques
were used to address signal transduction. In cAMP determination as-
says we observed that CRF treatment induced a significant increase in
cAMP levels, i.e. Gs-coupling of the CRF⁠2R. Orexin A decreased 0.5μM
Fig. 1. Expression and interaction of CRF⁠2 and orexin OX⁠1 receptors in a heterologous system. Panel A: Receptors expressed in HEK-293T cells transfected with 0.75μg cDNA for
CRF⁠2-YFP, 0.4μg cDNA for OX⁠1-RLuc or both were identified by YFP fluorescence (green) or by a monoclonal anti-RLuc (1/100) primary antibody and a cyanine-3-conjugated (1/200)
secondary antibody (red). Colocalization of both receptors is shown in yellow. Nuclei were stained with Hoechst (1/100, blue). Relative fluorescence intensity was 59 for CRF⁠2-YFP and
46 for OX⁠1-Rluc (SD<10%). Scale bar 20μm. Panel B: BRET was performed in HEK-293T cells expressing a constant amount of OX⁠1R-RLuc (0.4μg cDNA) (or GHS-R⁠1a-RLuc −0.75μg
cDNA-as negative control) and increasing amounts of CRF⁠2R-YFP (0.1–1.2μg cDNA) (Fig. 1B). Values are the mean±SEM of 6 different experiments. A schematic representation of the
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forskolin-induced cAMP levels, thus underscoring Gi-coupling of OX⁠1R
(Fig. 2A). Interestingly, coactivation with CRF and Orexin A induced
a signal similar to that obtained with CRF, indicating that CRF⁠2R en-
gagement blocks OX⁠1R coupling to Gi in the CRF⁠2R-OX⁠1R complex.
When cells were pretreated with K41498, the CRF⁠2R antagonist, a com-
plete inhibition of both the CRF and the Orexin A effects was ob-
served. Such cross-antagonism is an often-found property of GPCR het-
eromers (Franco et al., 2007). The pretreatment with the antagonist of
OX⁠1R, SB334867, offered a partial cross-antagonism when cells were
stimulated with CRF (Fig. 2A). In the analysis of calcium mobilization,
CRF induced no effect whereas Orexin A, consistent with canonical Gq
coupling of OX⁠1R, produced a transient response with a maximum of
cytosolic calcium concentration at 30 s after ligand addition. Interest-
ingly, coactivation with both ligands significantly reduced Orexin A-in-
duced effects. Moreover, cross-antagonism was found; in fact, not only
SB334867 but also K41498 inhibited the effect of Orexin A (Fig. 2B). In
ERK1/2 phosphorylation and label-free assays, the effect of either CRF
or Orexin A was significantly higher than that obtained when cells were
simultaneously treated with the two agonists (Fig. 2C and D). The re-
sults reflect allosteric interactions within the heteromer that impair sig-
naling when the two protomers are activated. Once more, a cross-antag-
onism phenomenon was detected as shown by the effect of antagonists
displayed in Fig. 2C and D. Taken together, the functional characteri-
zation of the CRF⁠2R-OX⁠1R complex results in finding a partial or total
cross-antagonism and an allosteric-driven negative cross-talk that was
more evident when quantifying the effect of Orexin A in the presence of
CRF.
2.3. Amphetamine potentiates CRF⁠2 and OX⁠1 receptor signaling in a
heterologous expression system
As the sensation of hunger is suppressed by amphetamine, we inves-
tigated whether the drug could affect CRF⁠2-OX⁠1 receptor heteromer-me-
diated signaling. HEK-293T cells transfected with the cDNA (0.6μg)
for CRF⁠2R were pretreated for 30min with amphetamine (2μM) (white
bars) or vehicle (black bars) and activated using CRF (100nM) (Fig. 3A
and B). The increase in cAMP levels (around 290%) was further en-
hanced by the drug (390%). Due to the lack of OX⁠1R expression, coac-
tivation with CRF and Orexin A provided in both conditions, with and
without amphetamine, similar results as with CRF (Fig. 3A). In OX⁠1R-ex-
pressing cells, Orexin A led to a reduction in the forskolin-induced cAMP
levels (24% reduction), that was potentiated (to 48% reduction) when
2μM amphetamine was added (Fig. 3B). Interestingly, similar results
were obtained when CRF⁠2R or OX⁠1R expressing cells (0.6μg cDNA each)
were analyzed by the DMR label-free assay (Fig. 3 C, D), i.e. a signifi-
cant increase in agonist-induced changes in cell mass density was found
in cells pretreated with amphetamine (2μM) for 30min. In agreement
with its coupling to a Gs protein, activation of the receptor in CRF⁠2R ex-
pressing HEK-293T cells did not led to alteration in cytoplasmic calcium
levels (Fig. 3E). In OX⁠1R-expressing cells, Orexin A produced a charac-
teristic peak of cytosolic calcium that was further increased with am-
phetamine (2μM) pretreatment. These results agree with those observed
in cAMP and DMR signals, indicating that amphetamine pretreatment
potentiates both CRF⁠2R and OX⁠1R G-protein-dependent signaling path-
ways. Finally, the MAPK activation assays showed that treatment with
100nM CRF in cells individually expressing CRF⁠2R increased by 2-fold
the basal levels of ERK1/2 phosphorylation and amphetamine pretreat-
ment led to a relatively small potentiation (Fig. 3G). In contrast, in cells
expressing OX⁠1R, the significant effect of 100nM Orexin A (>4-fold in-
crease over basal) was significantly reduced upon 2μM amphetamine
pretreatment (Fig. 3H). These results indicate that amphetamine im-
pacts on both CRF⁠2R- and OX⁠1R-mediated dependent signaling.
2.4. Amphetamine effects over CRF⁠2R depend on σ⁠1R expression
Corticotropin-releasing hormones act via two different receptors,
CRF⁠1R and CRF⁠2R. We have recently reported (Navarro et al., 2015)
the physical interaction between CRF⁠1R and σ⁠1R, demonstrating that
CRF⁠1R receptors participate in cocaine-dependent actions. It has also
been reported (Cobos et al., 2008; Nguyen et al., 2005) that different
drugs of abuse, cocaine and methamphetamine among them, may bind
Fig. 2. Functional characterization of the CRF⁠2-OX⁠1 heteroreceptor complex. HEK-293T cells transfected with 0.5μg cDNA for CRF⁠2 receptor and with 0.6μg cDNA for OX⁠1 receptor
were pretreated with the CRF⁠2 receptor antagonist, K41498 (1μM) or the OX⁠1 receptor antagonist SB334687 (1μM) followed by treatment with CRF (100nM), orexin A (100nM) or both.
cAMP levels (A), calcium release (B), ERK1/2 phosphorylation (C) and DMR (D) data were collected. In panel A data are represented in percentage (100% represented by the forskolin
effect) and were obtained in the presence of 0.5μM forskolin except when the effect of CRF, individually or in combination with other reagents, was assayed. In panel C data are repre-
sented in percentage over basal (100% represented by a dotted line). Values are the mean±SEM of 8 different experiments. In all cases, one way ANOVA followed by Bonferroni multiple
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Fig. 3. Amphetamine potentiates both, orexin- and CRF-induced signaling. HEK-293T cells transfected with 0.75μg cDNA for CRF⁠2 receptor (A, C, E, G) or with 1μg cDNA for OX⁠1
receptor (B, D, F, H) were pretreated with 2μM amphetamine (white bars) or vehicle (black bars) for 30min prior to CRF (100nM), orexin A (100nM) or combined treatments. cAMP lev-
els (A–B), calcium release (C–D), DMR (E–F) and ERK1/2 phosphorylation (G–H) data were collected. Data are given in percentage respect to basal (A) or respect to cAMP levels obtained
in the presence of 0.5μM forskolin (B); in A and B 100% a dotted line indicates the 100% value. Values are the mean±SEM of 7 different experiments. In all cases, one way ANOVA
followed by Bonferroni multiple comparison post hoc test showed a significant effect over basal (or over forskolin in the case of cAMP assays using orexin A)(*p < 0.05, **p < 0.01,
***p < 0.001), or amphetamine treatment versus vehicle (#p < 0.05, ##p < 0.01, ###p < 0.001).
to σ⁠1R. Accordingly, we wondered whether the amphetamine modula-
tion of CRF⁠2R action could be mediated by σ⁠1R. First, HEK-293T cells
were transfected with a constant amount of cDNA (0.3μg) for σ⁠1R-RLuc
and increasing amounts of cDNA for CRF⁠2R-YFP (0.1–1.5μg). A posi-
tive and saturable BRET curve, indicative of dimer formation, was ob-
tained (Fig. 4A). We subsequently addressed the potential of σ⁠1R to me-
diate the effect of amphetamine on CRF⁠2R by silencing σ⁠1R expression
using a siRNA approach. Importantly, we used HEK-293T cells express-
ing CRF⁠2R with (Fig. 4D) or without the siRNA (Fig. 4C) to determine
cAMP levels in cells pretreated for 30min with vehicle (black bars) or
with 2μM amphetamine (white bars). The results showed that cells with
silenced σ⁠1R, did not exhibit the amphetamine-modulating effect. It is
assumed that amphetamine potentiation of CRF-induced cAMP signal-
ing was due to binding of the drug to σ⁠1R and to the physical interaction
between CRF⁠2 and σ⁠1 receptors (Fig. 4D).
2.5. Amphetamine effects over OX⁠1R depend on σ⁠2R expression
It is known that OX⁠1R are not able to physically interact with σ⁠1R
(Navarro et al., 2015). Thus, it is difficult to understand how amphet-
amine could modulate Orexin A effects. It has been reported (Cobos
et al., 2008; Nguyen et al., 2005) that different drugs of abuse may
bind to σ⁠2R. To know whether amphetamine effects on OX⁠1R func-
tion could be due to the formation of a σ⁠2R-OX⁠1R complex, HEK-293T
cells expressing a constant amount of OX⁠1R-RLuc (0.35μg) and increas-
ing amounts of σ⁠2R-YFP (0.05–0.4μg) were assayed for BRET. A spe-
cific interaction between σ⁠2R and OX⁠1R receptors was deduced from
the saturable BRET curve (BRET⁠max 21±4, BRET⁠50 43±14) (Fig. 4B).
Functional studies were then undertaken in HEK-293T cells expressing
OX⁠1R and endogenous σ⁠2R (Fig. 4C) or in cells in which the expres-
sion of σ⁠2R was silenced by a specific siRNA (Fig. 4E). Amphetamine
(2μM) pretreatment only modulated the action of Orexin A action on
forskolin-induced cAMP levels when σ⁠2R was expressed. In summary,
amphetamine potentiation of receptor-G⁠i coupling seemed due to the
physical interaction between OX⁠1R and σ⁠2R.
2.6. Amphetamine potentiates the negative cross-talk displayed by the
OX⁠1R-CRF⁠2R heteromer
We next moved to test the effect of the drug of abuse on the
heteromer-mediated signaling. Immunocytochemistry assays were per-
formed in a heterologous expression system to investigate whether am-
phetamine could affect the expression of OX⁠1R-CRF⁠2R heteromers. OX⁠1R
was expressed at the plasma membrane level with no major changes
in cells pretreated with amphetamine, CRF⁠2R, which showed a mainly
intracellular expression in the absence of amphetamine, increased sur-
face expression in cells treated with the drug. Moreover, colocaliza-
tion between CRF⁠2R and OX⁠1R at the plasma membrane level increased
(Fig. 5A). To analyze the amphetamine effect over CRF⁠2R-OX⁠1R het-
eromeric complexes, a BRET assay was performed in cells expressing a
constant amount of OX⁠1R-RLuc and increasing amounts of CRF⁠2R-YFP.
Similar results were obtained in cells untreated (black line) or treated
with 2μM amphetamine (red line) (BRET⁠max 56±2, BRET⁠50 9±1 and
BRET⁠max 62±4, BRET⁠50 10±2, respectively) (Fig. 5B). These results
indicate that amphetamine does not significantly alter the physical in-
teraction between CRF⁠2R and OX⁠1R in the heteromeric complex. Fi-
nally, to assess any effect of amphetamine over the CRF⁠2R-OX⁠1R com-
plex, cAMP, ERK1/2 phosphorylation, calcium mobilization and la-
bel-free assays were performed in cotransfected cells pretreated with
receptor antagonists (1μM K41498 or 1μM SB334867) and with 2μM
amphetamine or vehicle. When receptors were activated using CRF
(100nM) or Orexin A (100nM), amphetamine potentiated both CRF-
and Orexin A-receptor-mediated. Remarkably, upon receptor coactiva-
tion, the negative cross-talk observed in the absence of amphetamine,
was not only maintained in the presence of the drug but it was poten-
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Fig. 4. CRF⁠2 receptors interact with σ⁠1 (sigma-1R) and OX⁠1 receptors interact with σ⁠2 receptors (sigma-2R). Panel A: HEK-293T cells were transfected with a constant amount of
cDNA (0.3μg) for σ⁠1R-RLuc and with increasing amounts of cDNA for CRF⁠2R-YFP (0.1–1.5μg). Values are the mean±SEM of 6 different experiments. Panel B: HEK-293T cells were trans-
fected with a constant amount of cDNA (0.35μg) for OX⁠1R-RLuc and with increasing amounts of cDNA for σ⁠2R-YFP (0.05–0.4μg). Values are the mean±SEM of 7 different experiments.
Panels C–E: HEK-293T cells transfected with 0.5μg cDNA for CRF⁠2 receptor and with 0.6μg cDNA for OX⁠1 receptor in the absence (C) or presence of siRNA (RNAi) for σ⁠1R (D) or for σ⁠2R
(E) were pretreated with 2μM amphetamine (white bars) or vehicle (black bars) for 30min prior to receptor activation using CRF (100nM), orexin A (100nM) or both. In panels C–E data
are represented in percentage and were obtained in the presence of 0.5μM forskolin except when the effect of CRF, individually or in combination with other reagents, was assayed (100%
-dotted line-is the basal level or the level obtained by 0.5μM forskolin treatment). Values are the mean±SEM of 8 different experiments. In all cases, one way ANOVA followed by Bon-
ferroni multiple comparison post hoc test showed a significant effect over basal (*p < 0.05**p < 0.01***p < 0.001, or amphetamine treatment versus vehicle (#p < 0.05, ##p < 0.01,
###p < 0.001).
also appeared when amphetamine was added to HEK-293T cells coex-
pressing CRF⁠2R and OX⁠1R. Altogether, it can be concluded that amphet-
amine addition exacerbates CRF⁠2R-OX⁠1R heteromer-mediated signaling.
2.7. Microdialysis experiments showed that amphetamine potentiates
Orexin A induced dopamine and glutamate release and in vivo cross-
antagonism
The ability of amphetamine to modulate the OX⁠1R function was ad-
dressed in a more physiological setup, namely in microdialysis experi-
ments performed in living animals. Data from these assays provide sur-
rogate measures for dopamine and glutamate release and/or interstitial
concentration in the VTA. Fig. 6A shows the typical placement of the mi-
crodialysis probe in the VTA, at 5.2mm posterior to bregma. As it can be
seen in Fig. 6B, in amphetamine-treated rats (white), infusion of Orexin
A (10μM) for 20min to VTA produced an increase in extracellular
dopamine (top) and glutamate release (bottom) compared to saline-con-
trol rats (black). These data agree with that obtained in HEK-293T cells
indicating that amphetamine treatment potentiates OX⁠1R function. Re-
markably, the increase of both extracellular dopamine (top) and gluta-
mate levels (bottom) was counteracted by a previous VTA infusion of
the CRF⁠2R selective antagonist K41498 (1μM) (Fig. 6C), demonstrating
the negative cross-antagonism previously described in HEK-293T cells.
These results are probably the first to report a cross-antagonism in in
vivo conditions.
3. Discussion
The results here presented provide evidence of a novel interaction
involving two GPCRs, OX⁠1R and CRF⁠2R, in both heterologous expres-
sion systems and natural sources. Two allosterically-mediated specific
properties of this heteroreceptor complex were i) a blockade by CRF of
OX⁠1R signaling and ii) a cross-antagonism, which was instrumental to
detect the heteromers even in living animals. A review on the unique-
ness of GPCR heteromers as example of the ability of antagonists of one
protomer to antagonize the signaling of another protomer in an het-
eroreceptor complex is provided elsewhere (Franco et al., 2016). The
structure of complexes formed by GPCRs and coupled G proteins is in-
strumental for heteromer-function (Cordomí et al., 2015). The negative
modulation of the effect of Orexin A by CRF suggests that some of the ef-
fects of Orexin A on the HPA (Spinazzi et al., 2006; Steiner et al., 2013)
occur at the level of receptors forming heteromers in brain cells. Our
results also constitute an underlying framework to address therapeutic
approaches to combat stress-related psychiatric disorders in which the
hypocretin/orexin system has a relevant role (reviewed in (James et
al., 2017). It should be noted that the expression of the orexin recep-
tor has been characterized in cells of the HPA axis (Czerwinska et al.,
2017). We also demonstrate that amphetamine modulates both OX⁠1R
and CRF⁠2R-mediated signaling and that the effect of the drug was me-
diated by sigma receptors forming heteromers with OX⁠1R and CRF⁠2R.
The overall mechanism constitutes an example of cytocrin signaling
that may underlie both short-term and long-term transcription-mediated
events (Navarro et al., 2017).
Two are the sigma receptors identified to date: the non-opioid re-
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Fig. 5. Amphetamine effect over CRF⁠2-OX⁠1 heteroreceptor complexes. Panel A: HEK-293T cells transfected with 0.75μg cDNA for CRF⁠2-YFP, 0.4μg cDNA for OX⁠1-RLuc or both were
pretreated with 2μM amphetamine for 30min. Receptors were identified by YFP fluorescence (green) or a monoclonal anti-RLuc (1/100) primary antibody and a cyanine-3-conjugated
(1/200) secondary antibody (red). Colocalization of the two receptors is shown in yellow. Nuclei were stained with Hoechst (1/100, blue). Relative fluorescence intensity was 47 for
CRF⁠2-YFP and 58 for OX⁠1-Rluc (SD<15%) (see legend of Fig. 1 for fluorescence intensity comparison). Scale bar: 20μm. Panel B: BRET was performed in HEK-293T cells transfected with
a constant amount of cDNA (0.4μg) for OX⁠1R-RLuc and increasing amounts of cDNA (0.2–1.5μg) for CRF⁠2R-YFP and treated with 2μM amphetamine (red line) or vehicle (black line) for
30min prior to data recording. Values are the mean±SEM of 7 different experiments. Panels C-F: HEK-293T cells transfected with 0.5μg cDNA for CRF⁠2 receptor and 0.6μg cDNA for
OX⁠1 receptor were pretreated with 2μM amphetamine (30min), further treated with the CRF⁠2 receptor antagonist K41498 (1μM) or the OX⁠1 receptor antagonist SB334687 (1μM), and
finally with CRF (100nM), Orexin A (100nM) or both. cAMP levels (C), calcium release (D), ERK1/2 phosphorylation (E) and DMR (F) data were collected. In panels C and E data are
represented in percentage over basal. In panel C data were obtained in the presence of 0.5μM forskolin except when the effect of CRF, individually or in combination with other reagents,
was assayed. Values are the mean±SEM of 8 different experiments. In all cases, one way ANOVA followed by Bonferroni multiple comparison post hoc test showed a significant effect
over basal (*p < 0.05**p < 0.01***p < 0.001). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Membrane Component 1 (PGRMC-1) protein is in doubt (Chu et al.,
2015). Despite endogenous ligands have not been yet identified, drugs
of abuse may interact with these two receptors at “physiologically” rel-
evant concentrations. Recent studies have demonstrated that cocaine
binding to σ⁠1R regulates GPCR signaling, likely, by means of direct in-
teraction between the σ⁠1R and, among other, dopamine D⁠1 (Navarro
et al., 2010) (Moreno et al., 2014) and D⁠2 receptors (Navarro et al.,
2013) and corticotropin-releasing factor CRF⁠1 receptor (Navarro et al.,
2015). Although its role as true receptor is not demonstrated, synthetic
agonists and antagonists are available for σ⁠1R. PRE-084 is considered
a selective agonist due to its ability to dose-dependently dissociate σ⁠1R
from a binding immunoglobulin protein/78kDa glucose-regulated pro-
tein (BiP/GPR-78) (Hayashi and Su, 2007). Once the agonist binds to
σ⁠1R, the receptor translocates to the plasma membrane and modulates
cell responses via protein-protein-interaction events related to ion han-
dling (Su et al., 2016; Wu and Bowen, 2008). Of special interest here
is the regulation of GPCR functionality. σ⁠1R not only binds cocaine but
methamphetamine and, therefore, drugs of abuse use σ⁠1R to mediate
some of their effects (Lever et al., 2016; Nguyen et al., 2005; Shull,
2002; Skuza, 1999). Drugs impeding the interaction of cocaine with σ⁠1R
are proposed to reduce drug-seeking behavior (Matsumoto et al., 2001).
There is evidence of σ⁠2R involvement in amphetamine effect on
dopamine transport (Izenwasser et al., 1998; Weatherspoon and
Werling, 1999). In addition, treatment with σ⁠2R antagonists counter-
acts cocaine-induced locomotor stimulation in mice (Guo and Zhen,
2015; Lever et al., 2014). Our results now point to a relevant role of
σ⁠2R on mediating effect of drugs of abuse and by mechanisms also in
volving interaction with GPCRs and modulation of their functionality.
Remarkably, we here report that the effect of amphetamine on CRF⁠2R
was mediated by σ⁠1R, whereas the effect of the drug on OX⁠1R was, in-
stead, mediated by σ⁠2R. Although direct studies with amphetamine have
not been reported, it is known that methamphetamine may bind to both
sigma receptors although with more affinity to the σ⁠1R (Nguyen et al.,
2005).
The results of microdialysis are relevant as they demonstrate that
Orexin A leads in the VTA to increases in interstitial concentration of
both dopamine and glutamate. The finding fits with hypocretin-medi-
ated increased glutamatergic neurotransmission in this area (Borgland
et al., 2008), with regulation of dopamine neuron activity driven by
prefrontal cortex activation (Moorman and Aston-Jones, 2010), with
fast scan cyclic voltammetry-based data on regulation of dopamine con-
centration in the nucleus accumbens shell (Patyal et al., 2012), and
with regulation of synaptic plasticity elicited by morphine (Baimel and
Borgland, 2015). Interestingly, CRF⁠2 receptor is expressed in VTA ter-
minals of neurons projecting from the hypothalamus (Slater et al.,
2016). The effect of local administration of amphetamine on increas-
ing VTA dopamine concentration was already reported in the nineties
(Byrnes and Wallace, 1997; Pan et al., 1996). Later on, differential ef-
fects due to different administration regimes of amphetamine (and of
cocaine) administration was reported (Zhang et al., 2001). In addition
a review on the evidence of glutamatergic and dopaminergic neuro-
transmission involvement in the behavioral actions exerted by amphet-
amine was provided (Vanderschuren and Kalivas, 2000). The media-
tion of GABA⁠B receptors on the alteration of glutamate and dopamine
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Fig. 6. Amphetamine potentiates orexin-induced extracellular glutamate and dopamine release in the VTA. Panel A: scheme extracted from the rat brain atlas (Paxinos and Wat-
son, 1986) and showing the placement of the microdialysis probe, at 5.2mm posterior to bregma, 0.7 lateral and 8.7mm ventral. Panel B: Infusion in VTA of orexin A (10μM) for 20min
(vertical grey bars) was followed by determination of dopamine (DA, top) and Glutamate (Glut, bottom) levels. Data from saline infusion are in black and data from amphetamine-treated
rats are in white. Panel C: effect of VTA infusion of Orexin A (10μM) for 20min (vertical grey bars) after 20min treatment with the CRF⁠2R antagonist K41489 (1μM, horizontal black line)
on extracellular dopamine (DA, top) and glutamate (Glu, bottom) release. Data from control rats are in black and data from amphetamine-treated rats are in white. In panels B and C data
are represented in percentage over basal. Values are the mean±SEM of 5 different experiments. In all cases, Two-way ANOVA followed by Bonferroni multiple comparison post hoc test
showed a significant effect over basal (*p < 0.05; ****<p < 0.0001).
et al., 2002). Interestingly, evidence points that metabotropic but not
ionotropic receptors in the nucleus accumbens, are involved in the am-
phetamine-mediated increase in dopamine efflux/levels (Darracq et al.,
2001). It is however intriguing that amphetamine may block “inhibitory
glutamate transmission in dopamine neurons” (Paladini et al., 2001).
Finally, our results suggest that σ⁠2R may, at least partially, mediate
the hunger-suppressive action of amphetamine by interacting with orex-
igenic receptors in CRF⁠2R-OX⁠1R heteromer contexts. Despite extensive
evidence supporting the formation of GPCR oligomers in heterologous
systems, the lack of appropriate methodology makes controversial their
existence in their native environment. A specific pharmacological prop-
erty for the heterodimeric receptor complex is critical for identify such
signaling complexes in native tissue. In the present study, we observed
that Orexin A caused an increase of extracellular dopamine and gluta-
mate levels in the VTA that was counteracted by a previous VTA infu-
sion of a CRF2R selective antagonist. These microdialysis experiments
demonstrate the negative cross-antagonism previously described in vitro
and confirm that this dimeric entity is functionally relevant in vivo. To
our knowledge, this is the first report showing in vivo GPCR heteromer
identification by cross-antagonism. Thus, the present study conveys a
novel approach to add to those that allow identification of GPCR het-
eromers in natural sources (Franco et al., 2016).
4. Materials and methods
4.1. Reagents
Orexin A, CRF, SB334867 and K41498 were purchased from Tocris
Bioscience (Bristol, UK). DL-Amphetamine hydrochloride was pur-
chased from Sigma-Aldrich (St. Louis, MO). For the microdialysis ex-
periments, amphetamine sulfate was donated by Laboratorio Chile S.A
(Nuñoa, Santiago, Chile).
4.2. Cell lines
HEK-293T cells were grown in DMEM (Gibco, Thermo Fisher Scien-
tific, Halethorpe, MD) supplemented with 2mM L-glutamine, 100μg/ml
sodium pyruvate, 100 units/mL penicillin/streptomycin, minimum Ea-
gle's medium non-essential amino acid solution (1/100) and 5% (v/v)
heat-inactivated Fetal Bovine Serum (FBS) (all supplements were from
Invitrogen, Paisley, Scotland, UK).
4.3. Expression vectors and fusion proteins
Human cDNAs for CRF⁠2 receptor, OX⁠1 receptor, σ⁠1 receptor, σ⁠2 re-
ceptor and GHS-R1a cloned into pcDNA3.1, were amplified without
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lowing: EcoRI and KpnI sites to clone OX⁠1 receptor and σ⁠2 receptor
in the pcDNA3.1RLuc vector (pRLuc-N1, PerkinElmer Life Sciences,
Wellesley, MA) and to clone CRF⁠2 receptor and GHS-R1a in the
pEYFP–N1 vector (enhanced yellow variant of GFP; Clontech, Heidel-
berg, Germany); HindIII and BamHI sites to clone σ⁠1R in pEYFP–N1 vec-
tor; EcoRI and BamHI sites to clone A⁠2A receptor in pEYFP–N1 vector.
Amplified fragments were subcloned to be in-frame with restriction sites
of pRLuc-N1 or pEYFP-N1 vectors to provide plasmids that express pro-
teins fused to RLuc or YFP on the C-terminal end (OX⁠1-RLuc, CRF⁠2-YFP,
GHS-R1a-YFP, σ⁠1R-RLuc and σ⁠2R-RLuc).
4.4. Cell transfection
HEK-293T cells growing in 6-well dishes were transiently transfected
with the corresponding protein cDNA by the PEI (Sigma-Aldrich, St.
Louis, MO) method. Cells were incubated with the corresponding cDNA
together with PEI (5.47mM in nitrogen residues) and 150mM NaCl in
a serum-starved medium. After 4h, the medium was changed to a fresh
complete culture medium. Cells were maintained at 37 °C in a humid at-
mosphere of 5% CO⁠2.
4.5. Resonance energy transfer-based assays
For BRET assays (Hinz et al., 2018), HEK-293T cells were transiently
co-transfected with a constant amount of cDNA encoding for recep-
tor-RLuc and with increasing amounts of cDNA corresponding to re-
ceptor-YFP. 24 h after transfection, cells were adjusted to 20μg of pro-
tein using a Bradford assay kit (Bio-Rad, Munich, Germany) and bovine
serum albumin for standardization. To quantify fluorescence proteins,
cells were distributed in 96-well black microplates with a transparent
bottom (Corning 3600, Corning, NY), and the fluorescence was read
in a Fluostar Optima fluorimeter (BMG Labtech, Offenburg, Germany)
equipped with a high-energy xenon flash lamp using a 10nm band-
width excitation filter at 485nm for receptor-YFP reading. Receptor
fluorescence expression was determined as fluorescence of the sam-
ple minus the fluorescence of cells expressing receptor-RLuc alone. For
BRET measurements, cells were distributed in 96-well white microplates
with white bottoms (Corning) and 5μM of coelenterazine H (Molecu-
lar Probes, Eugene, OR) was added. One minute after adding coelenter-
azine H, BRET was determined using a Mithras LB 940 reader (Berthold
Technologies, Bad Wildbad, Germany), which allows the integration
of the signals detected in the short-wavelength filter at 485nm and
the long-wavelength filter at 530nm. To quantify protein-RLuc expres-
sion, luminescence readings were performed 10min after 5μM coelen-
terazine H addition using a Mithras LB 940. The net BRET is defined
as [(long-wavelength emission)(short-wavelength emission)]-Cf, where
Cf corresponds to [(long-wavelength emission)/(short-wavelength emis-
sion)] for the donor construct expressed alone in the same experiment.
GraphPad Prism software (San Diego, CA, USA) was used to fit data.
BRET is expressed as mili BRET units, mBU (net BRET x 1000).
4.6. Immunocytochemistry
Transiently transfected HEK-293T cells were incubated 30min with
vehicle or 2μM amphetamine and immediately, cells were fixed in 4%
paraformaldehyde for 15min and washed twice with PBS containing
20mM glycine (buffer A) to quench the aldehyde groups. After per-
meabilization with buffer A containing 0.2% Triton X-100 for 5min,
cells were treated with PBS containing 1% bovine serum albumin. Af-
ter 1hat room temperature, cells expressing receptor-RLuc were labeled
with a primary mouse monoclonal anti-RLuc antibody (1/100, EMD
Millipore, Darmstadt, Germany) for 1h, washed, and stained with a
secondary antibody for Cy3 donkey anti-mouse (1/100, Jackson Im-
munoResearch Laboratories, Baltimore, MD). Receptors fused to YFP
were detected by their fluorescent properties. Cell nuclei were stained
with Hoechst (Sigma-Aldrich). Samples were washed, mounted with
30% Mowiol (Calbiochem) and observed under a Leica SP2 confocal
microscope (Leica Microsystems, Mannheim, Germany). Using the Fiji
package (pacific. mpi-cbg.de), fluorescence intensity was analyzed in
the different channels in 5 areas of 10 different cells.
4.7. Dynamic mass redistribution assays (DMR)
Cell mass redistribution induced upon receptor activation were de-
tected by illuminating the underside of a biosensor with polychromatic
light and measuring the changes in the wavelength of the reflected
monochromatic light that is a sensitive function of the index of re-
fraction. The magnitude of this wavelength shift (in picometers) is di-
rectly proportional to the amount of DMR. HEK-293T cells were seeded
in 384-well sensor microplates to obtain 70–80% confluent monolay-
ers constituted by approximately 10,000cells per well. Previous to the
assay, cells were washed twice with assay buffer (HBSS with 20mM
HEPES, pH 7.15) and incubated 2h with assay-buffer (24 °C, 30 μl/well).
Hereafter, the sensor plate was scanned and a baseline optical signa-
ture was recorded for 10min before adding 10μl of amphetamine or
the specific antagonists 30min prior to agonist stimulation; all test com-
pounds were dissolved in assay buffer. The cell signaling signature was
determined using an EnSpire⁠® Multimode Plate Reader (PerkinElmer)
by a label-free technology. Then, DMR responses were monitored for at
least 4000s. Results were analyzed using EnSpire Workstation Software
v 4.10.
4.8. Intracellular calcium release
Cells were co-transfected with the cDNA for the indicated receptors
and 0.75μg of GCaMP6 calcium sensor (Chen et al., 2013) using the
PEI method. 24h after transfection, 150,000cells/well in 96-well black,
clear-bottom microtiter plates were incubated with Mg⁠+2-free Locke's
buffer (pH 7.4) (154mM NaCl, 5.6mM KCl, 3.6mM NaHCO⁠3, 2.3mM
CaCl⁠2, 5.6mM glucose and 5mM HEPES) supplemented with 10μM
glycine, and receptor ligands were added as indicated (antagonists were
added 10min bafore agonist stimulation). The fluorescence emission in-
tensity of GCaMP6 was recorded at 515nm upon excitation at 488nm
on the EnSpire⁠® multimode plate reader for 335s every 15s and 100
flashes/well.
4.9. cAMP Accumulation
Homogeneous time-resolved fluorescence energy transfer assays
were performed using the Lance Ultra cAMP kit (PerkinElmer Life Sci-
ences) (Navarro et al., 2018, 2016). The optimal cell density was first es-
tablished for an appropriate fluorescent signal by measuring the time-re-
solved FRET signal as a function of 0.5μM forskolin concentration us-
ing different cell densities. Forskolin dose-response curves were related
to the cAMP standard curve to establish which cell density provides a
response that covers most of the dynamic range of the cAMP standard
curve. Cells growing in medium containing 50μM zardeverine were pre-
treated with vehicle or 2μM amphetamine for 30min at 25 °C. Then,
3000 HEK-293T cells/well in 384-well microplates were treated with
the antagonists or the corresponding vehicle for 15min and stimulated
with agonists for 15min before adding 0.5μM forskolin or vehicle and
incubating for an additional 15-min period. Fluorescence at 665nm was
analyzed on a PHERAstar Flagship microplate reader equipped with a
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4.10. ERK phosphorylation assays
To determine ERK1/2 phosphorylation, 40,000cells/well were
placed in transparent Deltalab 96-well microplates and kept at the in-
cubator for 24h. Then, cells were transfected using the PEI method and
incubated for a 48h period. 2–4h before the experiment, the medium
was substituted by serum-starved DMEM medium. Then, cells were
pre-treated at 25 °C for 10min with vehicle or antagonists in
serum-starved DMEM medium and treated for 7min with agonists. Cells
were then washed twice with cold PBS before addition of lysis buffer
(20min treatment in agitation). 10μL of each supernatant were placed
in white ProxiPlate 384-well microplates and ERK 1/2 phosphorylation
was determined using AlphaScreen⁠®SureFire⁠® kit (Perkin Elmer) follow-
ing the instructions of the supplier and using an EnSpire⁠® Multimode
Plate Reader (PerkinElmer, Waltham, MA, USA).
4.11. Animals
Male Sprague-Dawley rats weighing 200–230g were selected for the
experiments. They were kept in a controlled environment with a 12-h
light-dark cycle and at 21 °C room temperature. Food and water were
provided ad libitum. All experimental procedures were approved by the
Ethics Committee of Faculty of Biological Sciences of “Pontificia Uni-
versidad Católica de Chile” and follow the international guidelines (NIH
Guide for the Care and Use of Laboratory Animals).
4.12. Experimental procedure
Animals keep housing and handling in colony for 3 days once of ar-
rived and then were divided randomly into two groups that received
injection of either AMPH (1.5mg/kg, i.p) or an equivalent volume
of saline solution once per day. The procedure was carried out at
10:00–11:00 a.m., once a day for a five consecutive days. After 5 days
of abstinence, microdialysis experiment was performed.
4.13. Microdialysis and analysis of samples
The animals were deeply anesthetized with chloral hydrate (400mg/
kg, i.p). Body temperature of the animals was maintained at 37 °C
with an electrical blanket controlled by a thermostat. A quarter of
the initial dose of chloral hydrate was given every hour to maintain
the animal anesthetized during the course of the experiments. Concen-
tric brain microdialysis probes, 2mm in length (CMA 12, CMA Micro-
dialysis AB, Solna, Sweden) were implanted in the VTA. The coordi-
nates used, according to the atlas of Paxinos and Watson (1986), were:
VTA: antero-posterior (AP): 5.2mm, medial-lateral (ML) 0.7mm and
dorso-ventral (DV) −8.7mm. Microdialysis probes were perfused with
Krebs-Ringer´s phosphate buffer whit 0.02% BSA (KRP-BSA) at a rate of
2μL/min using a Harvard infusion pump (Model 22; Dover, MA, USA).
After a 90min stabilization period, 10min samples were collected in
4μL of 0.2M perchloric acid. K411498 (1μM) and orexina A (10 μM)
were added intra-VTA in the perfusion media as indicated in the re-
spective figures. At the end of each experiment, animals were killed by
decapitation and brains quickly removed and stored in formalin. Brain
coronal sections of 30μm were stained with Cresyl violet to verify probe
location under microscope.
4.13.1. Analysis of dialysate samples
HPLC-amperometric quantification of dopamine was performed as
described previously (Galleguillos et al., 2010). HPLC-fluorometric de-
termination for amino acids was performed as described previously
(Sotomayor-Zarate et al., 2010).
4.13.2. Analysis of dialysate samples
HPLC-amperometric quantification of dopamine was performed as
described previously (Galleguillos et al., 2010). HPLC-fluorometric de-
termination for amino acids was performed as described previously
(Sotomayor-Zárate et al., 2010).
4.13.3. Analysis of dialysate samples
HPLC-amperometric quantification of dopamine was performed as
described previously (Galleguillos et al., 2010). HPLC-fluorometric de-
termination for amino acids was performed as described previously
(Sotomayor-Zarate et al., 2010).
HPLC-electrochemical determination of dopamine was performed
as previously described (Sotomayor et al., 2005). The retention time
for dopamine was 11.0min and the detection limit was 0,1 fmol/μL.
HPLC-fluorometric determination of glutamate was performed as previ-
ously described (Sotomayor-Zárate et al., 2010). The retention time for
glutamate was 2.8min and the detection was 5 fmol/μL.
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